logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Musculoskeletal (Rheum/Ortho) drugs

    FiltersReset Filters
    36 results

    • amjevita

      (adalimumab-atto)
      Amgen Inc
      Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

    • benlysta

      (belimumab)
      GlaxoSmithKline LLC
      Usage: BENLYSTA (belimumab) is indicated for patients aged 5 and older with active systemic lupus erythematosus and active lupus nephritis, both receiving standard therapy. Its efficacy in severe active central nervous system lupus is not evaluated, hence it is not recommended for such cases.

    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

    • ilaris

      (canakinumab)
      Novartis Pharmaceuticals Corporation
      Usage: ILARIS (canakinumab) is indicated for treating autoinflammatory Periodic Fever Syndromes, including CAPS, TRAPS, HIDS/MKD, and FMF; active Still's Disease in patients 2 years and older; and symptomatic treatment of gout flares in adults when other treatments are unsuitable.

    • inveltys

      (loteprednol etabonate)
      ALCON LABORATORIES, INC.
      Usage: INVELTYS is a corticosteroid indicated for reducing post-operative inflammation and pain after ocular surgery.

    • kevzara

      (sarilumab)
      sanofi-aventis U.S. LLC
      Usage: KEVZARA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis and polymyalgia rheumatica who have had inadequate responses to DMARDs or corticosteroids. It is also indicated for active polyarticular juvenile idiopathic arthritis in patients weighing 63 kg or more.

    • krystexxa

      (pegloticase)
      Horizon Therapeutics USA, Inc.
      Usage: KRYSTEXXA (pegloticase) is indicated for treating chronic gout in adult patients who are refractory to conventional therapy, meaning they have not achieved normalized serum uric acid levels or adequately controlled symptoms with maximum doses of xanthine oxidase inhibitors. It is not recommended for asymptomatic hyperuricemia.

    • lotemax sm

      (loteprednol etabonate)
      Bausch & Lomb Incorporated
      Usage: LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% is indicated for the treatment of post-operative inflammation and pain after ocular surgery.

    • lupkynis

      (Voclosporin)
      Aurinia Pharma U.S., Inc.
      Usage: LUPKYNIS is indicated for the treatment of adult patients with active lupus nephritis (LN) in combination with a background immunosuppressive therapy. Its safety and efficacy have not been established with cyclophosphamide, and its use in this context is not recommended.

    • lyrica

      (PREGABALIN)
      Parke-Davis Div of Pfizer Inc
      Usage: LYRICA is indicated for managing neuropathic pain related to diabetic peripheral neuropathy and spinal cord injury, postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial-onset seizures in patients aged 1 month and older.